ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      Subscribe Login/Register Profile Icon
      S&P 500
      5,011.12
      -0.22%
      US Tech 100
      16,880.80
      -0.90%
      Dow Jones
      37,775.38
      0.06%
      Brent Oil
      88.29
      2.17%
      Bitcoin
      62,179.73
      -2.09%
      Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ
      6. Incyte Corporation (INCY)

      7. Incyte Corporation (INCY) News

      INCY

      Incyte (INCY)

      Incyte Corporation
      		Date:
      Sort by:
       Showing the most relevant articles for your search:NASDAQ:INCY
      DateTimeSourceHeadlineSymbolCompany
      04/11/20248:00AMBusiness WireIncyte to Report First Quarter Financial ResultsNASDAQ:INCYIncyte Corporation
      04/01/20248:30AMBusiness WireIncyte and CMS Announce Collaboration and License Agreement for Povorcitinib, an Oral JAK1 Inhibitor, in Mainland China, Hong Kong, Macau, Taiwan and Southeast AsiaNASDAQ:INCYIncyte Corporation
      03/29/20244:30PMBusiness WireIncyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:INCYIncyte Corporation
      03/11/20248:57AMBusiness WireIncyte gibt neue Daten aus Phase-2-Studie zur Untersuchung von Ruxolitinib-Creme (Opzelura®) bei Patienten mit leichter bis mittelschwerer Hidradenitis Suppurativa bekanntNASDAQ:INCYIncyte Corporation
      03/11/20248:57AMBusiness WireIncyte annonce de nouvelles données de l’étude de phase 2 évaluant le ruxolitinib crème (Opzelura®) chez les patients atteints d’hidradénite suppurée légère à modéréeNASDAQ:INCYIncyte Corporation
      03/11/20246:06AMBusiness WireIncyte présente de nouvelles données de l’étude de phase 2 évaluant le povorcitinib chez des patients atteints de prurigo nodulaireNASDAQ:INCYIncyte Corporation
      03/11/20245:53AMBusiness WireIncyte legt neue brandaktuelle Daten aus Phase-2-Studie zur Prüfung von Povorcitinib bei Patienten mit Prurigo nodularis vorNASDAQ:INCYIncyte Corporation
      03/10/20244:05PMBusiness WireIncyte Presents New Late-Breaking Data from Phase 2 Study Evaluating Povorcitinib in Patients with Prurigo NodularisNASDAQ:INCYIncyte Corporation
      03/10/20244:05PMBusiness WireIncyte Announces New Data from Phase 2 Study Evaluating Ruxolitinib Cream (Opzelura®) in Patients with Mild-to-Moderate Hidradenitis SuppurativaNASDAQ:INCYIncyte Corporation
      03/04/20242:38PMBusiness WireDe nouvelles données dérivées du portefeuille dermatologique croissant d’Incyte seront présentées lors de l’assemblée annuelle 2024 de l’American Academy of Dermatology (AAD)NASDAQ:INCYIncyte Corporation
      03/04/20242:02PMBusiness WireNeue Daten aus dem wachsenden Dermatologieportfolio von Incyte werden bei Jahresversammlung 2024 der American Academy of Dermatology (AAD) präsentiertNASDAQ:INCYIncyte Corporation
      03/04/20248:00AMBusiness WireNew Data from Incyte’s Growing Dermatology Portfolio to be Presented at the 2024 American Academy of Dermatology (AAD) Annual MeetingNASDAQ:INCYIncyte Corporation
      02/29/202410:19AMBusiness WireIncyte Launches The Unseen Journey to Elevate the Hidden Impact of Myeloproliferative Neoplasms (MPNs) on Patients’ Lives through Generative AINASDAQ:INCYIncyte Corporation
      02/29/20247:30AMGlobeNewswire Inc.Knight Therapeutics Announces Launch of Minjuvi® in BrazilNASDAQ:INCYIncyte Corporation
      02/28/20249:11AMBusiness WireIncyte annonce que la Food and Drug Administration des États-Unis accorde une évaluation prioritaire à l’axatilimab pour le traitement de la maladie chronique du greffon contre l’hôteNASDAQ:INCYIncyte Corporation
      02/28/20247:15AMBusiness WireIncyte gibt bekannt, dass die US-Arzneimittelbehörde FDA Axatilimab für die Behandlung der chronischen Graft-Versus- Host-Krankheit als vorrangig eingestuft hatNASDAQ:INCYIncyte Corporation
      02/27/20244:08PMBusiness WireIncyte Announces U.S. Food and Drug Administration Grants Priority Review for Axatilimab for the Treatment of Chronic Graft-Versus-Host DiseaseNASDAQ:INCYIncyte Corporation
      02/16/20244:04PMEdgar (US Regulatory)Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend]NASDAQ:INCYIncyte Corporation
      02/16/202412:50PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:INCYIncyte Corporation
      02/16/202412:50PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:INCYIncyte Corporation
      02/16/202412:49PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:INCYIncyte Corporation
      02/16/202412:49PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:INCYIncyte Corporation
      02/16/202412:48PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:INCYIncyte Corporation
      02/16/202412:47PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:INCYIncyte Corporation
      02/15/20248:00AMBusiness WireIncyte to Present at Upcoming Investor ConferenceNASDAQ:INCYIncyte Corporation
      02/14/202412:33PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:INCYIncyte Corporation
      02/13/20245:06PMEdgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:INCYIncyte Corporation
      02/13/20244:03PMEdgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:INCYIncyte Corporation
      02/13/20247:03AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:INCYIncyte Corporation
      02/13/20247:00AMBusiness WireIncyte Reports 2023 Fourth Quarter and Year-End Financial Results, Provides 2024 Financial Guidance and Highlights R&D PrioritiesNASDAQ:INCYIncyte Corporation
       Showing the most relevant articles for your search:NASDAQ:INCY